The study shows that while NALCN promoter methylation in NSCLC tissues provides valuable prognostic information, further research is needed to validate its potential as a non-invasive biomarker in plasma CTDNA in a larger cohort of patients. Here, NALCN is linked to non-small cell lung carcinoma.